top of page
  • mmahomed2

Seed investment from The House Fund

Valitor is proud to announce that we have received a seed investment from The House Fund. These funds will augment our current SBIR funding by accelerating the commercialization of our lead therapeutic product for indications in ophthalmology. 

33 views0 comments

Recent Posts

See All

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

bottom of page